Avenue Therapeutics Company Top Insiders
| ATXI Stock | USD 0.36 0.02 5.26% |
Avenue Therapeutics employs about 3 people. The company is managed by 5 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 0.6 employees per reported executive. Assessment of Avenue Therapeutics' management performance can provide insight into the firm performance.
| Srinivas Subramanian President Executive President |
Avenue |
Avenue Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (4.7194) % which means that it has lost $4.7194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.351) %, meaning that it created substantial loss on money invested by shareholders. Avenue Therapeutics' management efficiency ratios could be used to measure how well Avenue Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Avenue Therapeutics Workforce Comparison
Avenue Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 152. Avenue Therapeutics claims roughly 3.0 in number of employees contributing just under 2% to equities under Health Care industry.
Avenue Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avenue Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avenue Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Avenue Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Herskowitz Neil over three weeks ago Acquisition by Herskowitz Neil of 2500 shares of Avenue Therapeutics at 3.99 subject to Rule 16b-3 | ||
Fortress Biotech, Inc. over two months ago Insider Trading | ||
Herskowitz Neil over three months ago Acquisition by Herskowitz Neil of 10000 shares of Avenue Therapeutics at 9.31 subject to Rule 16b-3 | ||
Herskowitz Neil over three months ago Disposition of tradable shares by Herskowitz Neil of Avenue Therapeutics at 2.0 subject to Rule 16b-3 | ||
David Jin over three months ago Acquisition by David Jin of 250000 shares of Avenue Therapeutics at 1.14 subject to Rule 16b-3 | ||
Kranzler Jay D over three months ago Disposition of tradable shares by Kranzler Jay D of Avenue Therapeutics at 2.24 subject to Rule 16b-3 | ||
Paley Jeffrey over three months ago Acquisition by Paley Jeffrey of 14663 shares of Avenue Therapeutics subject to Rule 16b-3 | ||
Kranzler Jay D over three months ago Acquisition by Kranzler Jay D of 497 shares of Avenue Therapeutics at 2.5 subject to Rule 16b-3 |
Avenue Therapeutics Notable Stakeholders
An Avenue Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Avenue Therapeutics often face trade-offs trying to please all of them. Avenue Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Avenue Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Srinivas Subramanian | Executive President | Profile | |
| Lindsay Rosenwald | Executive Director | Profile | |
| Xiaoqin MD | Consultant | Profile | |
| Alexandra MD | Chief Officer | Profile | |
| David Jin | COO CFO | Profile |
About Avenue Therapeutics Management Performance
The success or failure of an entity such as Avenue Therapeutics often depends on how effective the management is. Avenue Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Avenue management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Avenue management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acuteintensive care hospital setting. The company was incorporated in 2015 and is based in New York, New York. Avenue Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Avenue Therapeutics Workforce Analysis
Traditionally, organizations such as Avenue Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Avenue Therapeutics within its industry.Avenue Therapeutics Manpower Efficiency
Return on Avenue Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.5M | |
| Net Loss Per Executive | 2.1M | |
| Working Capital Per Employee | 218K | |
| Working Capital Per Executive | 130.8K |
Complementary Tools for Avenue Pink Sheet analysis
When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |